Analysts’ Recent Ratings Updates for Nkarta (NKTX)

Nkarta (NASDAQ: NKTX) recently received a number of ratings updates from brokerages and research firms:

• 12/20/2025 – Nkarta was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 12/15/2025 – Nkarta had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – Nkarta had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/7/2025 – Nkarta was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 11/29/2025 – Nkarta was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 11/15/2025 – Nkarta was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 11/11/2025 – Nkarta had its price target lowered by analysts at Stifel Nicolaus from $12.00 to $11.00. They now have a “buy” rating on the stock.
• 10/31/2025 – Nkarta had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.

Nkarta, Inc is a clinical-stage biotechnology company specializing in the development of off-the-shelf natural killer (NK) cell therapies for the treatment of cancer. Leveraging proprietary activation and expansion technologies, Nkarta aims to harness the innate tumor-killing properties of NK cells while incorporating targeted immuno-engineering approaches to enhance safety, potency and persistence in patients. The company’s platform supports both allogeneic cell manufacturing and genetic modifications to generate chimeric antigen receptor-expressing NK cell candidates designed to address a range of hematologic and solid tumors.

Nkarta’s lead program, NKX019, is an anti-CD19 CAR-NK cell therapy in early-phase clinical trials for relapsed or refractory B-cell malignancies.